Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Motorsport Games Inc. (NASDAQ:MSGM) shares jumped 770% to $22.99. The company announced a debt-for-equity exchange with Motorsport Network. Also, Investor Mike Zoi reported purchase of 338,98
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersHillstream BioPharma (NASDAQ:HILS) stock rose 95.2% to $1.31 during Tuesday's regular session. As of 12:30 EST, Hillstream BioPharma's stock is trading at a volume of 61.7 million, which is 199
Why Applied UV Shares Are Trading Higher By 46%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers FOXO Technologies Inc. (NYSE:FOXO) shares jumped 109% to $1.07.Akanda Corp. (NASDAQ:AKAN) rose 59% to $0.4459 after jumping 47% on Thursday.Applied UV, Inc. (NASDAQ:AUVI) gained 46.1% to $1.52
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersRedhill Biopharma (NASDAQ:RDHL) stock rose 35.0% to $0.25 during Friday's pre-market session. The market value of their outstanding shares is at $22.6 million. Akanda (NASDAQ:AKAN) stock moved
Top 5 Health Care Stocks That May Dip
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when
Analysts Issue Forecasts for NewAmsterdam Pharma's FY2027 Earnings (NASDAQ:NAMS)
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients a
NewAmsterdam Pharma (NASDAQ:NAMS) Expected to Post FY2027 Earnings of ($0.16) Per Share
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Equities research analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for shares of NewAmsterdam Pharma in a report iss
NAMS Stock Trading Resumes
NAMS Stock Trading Halted, Volatility Trading Pause
Newly Listed NewAmsterdam Pharma Touts Encouraging Data From High Cholesterol Treatment
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) announced topline results from ROSE2 Phase 2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.Ne
Loading...
No Stock Yet